EDEMANN Furosemide 40mg Tablet 1's
RXDRUG-DR-XY25904-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Edemann
Full Details
Dosage Strength
40mg
Drug Ingredients
- Furosemide
Drug Packaging
Tablet 1's
Generic Name
Furosemide
Dosage Form
Tablet
Registration Number
DR-XY25904
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
Edema: Treatment of edema in adults, infants and children associated with congestive heart failure, cirrhosis of the liver and renal disease, including nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Adjunctive therapy in acute pulmonary edema.
Hypertension: Alone or in combination with other antihypertensive agents in adults. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.
Hypertension: Alone or in combination with other antihypertensive agents in adults. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.
Dosage/Direction for Use
Adults: ½-1 tablet/dose, frequency as prescribed by physician.
Administration
May be taken with or without food: May be taken w/ meals to reduce GI discomfort.
Contraindications
Hepatic cirrhosis & ascites, hepatic coma, severe electrolyte depletion, hypokalemia & metabolic alkalosis, severe progressive renal disease.
Warnings
Furosemide is a potent diuretic, which, if given in excessive amount, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose schedule must be adjusted to the individual patient's needs.
In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis.
Supplemental potassium chloride and, if required, aldosterone antagonists are helpful in preventing hypokalemia and metabolic alkalosis if increasing azotemia and oliguria occur during treatment of severe progressive renal disease.
Furosemide should be discontinued in cases of tinnitus since reversible and irreversible hearing impairment have been reported. Usually, reports indicate that diuretic treatment with furosemide in the 1st few weeks in premature neonates with respiratory distress syndrome may increase the risk of persistent patent ductus arteriosus (PDA), possibly through a prostaglandin E-mediated process.
In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis.
Supplemental potassium chloride and, if required, aldosterone antagonists are helpful in preventing hypokalemia and metabolic alkalosis if increasing azotemia and oliguria occur during treatment of severe progressive renal disease.
Furosemide should be discontinued in cases of tinnitus since reversible and irreversible hearing impairment have been reported. Usually, reports indicate that diuretic treatment with furosemide in the 1st few weeks in premature neonates with respiratory distress syndrome may increase the risk of persistent patent ductus arteriosus (PDA), possibly through a prostaglandin E-mediated process.
Special Precautions
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possible vascular thrombosis and embolism, particularly in elderly patients. As with any effective diuretic, electrolyte depletion may occur during furosemide therapy especially in patients receiving higher doses and restricted salt intake.
Drug Interactions
Furosemide may increase blood glucose in diabetes mellitus. Skin of some patients may be more sensitive to the effects of sunlight while taking furosemide.
Furosemide may increase the ototoxic potential of aminoglycoside antibiotics.
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
Furosemide has a tendency to antagonize the skeletal muscle-relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.
Furosemide may decrease arterial responsiveness to norepinephrine.
Furosemide may increase the ototoxic potential of aminoglycoside antibiotics.
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
Furosemide has a tendency to antagonize the skeletal muscle-relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.
Furosemide may decrease arterial responsiveness to norepinephrine.
Storage
Store at a temperature not exceeding 30°C.
Action
Diuretic/antihypertensive.
MedsGo Class
Diuretics
Please sign in so that we can notify you about a reply